Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether acute ionized hypomagnesemia and hypocalcemia immediately following foscarnet infusions can be lessened or eliminated by prior infusion of magnesium sulfate. To determine whether reductions in ionized magnesium, ionized calcium, and parathyroid hormone levels following foscarnet infusions are lessened by preinfusion of magnesium sulfate. To evaluate the safety of intravenous magnesium sulfate prior to foscarnet infusion by monitoring blood pressure, heart rate, and heart rhythm. To characterize the effect of magnesium sulfate on foscarnet blood levels and urinary excretion of calcium, magnesium, phosphate, and foscarnet.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astra USA
• Treatments: Foscarnet; Magnesium Sulfate; Phosphonoacetic Acid

Criteria

Inclusion Criteria

Patients must have:

• AIDS by CDC criteria.

• Documented CMV disease.

• Tolerance of foscarnet dose of 90 mg/kg bid.

• Normal serum calcium, serum creatinine, and serum phosphate.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Known allergy to Foscarnet.

• In extremis or incapacitated because of underlying illness (e.g., comatose or tracheally intubated).

• Volume depletion.

Concurrent Medication:

Excluded:

• Nephrotoxic drugs such as IV pentamidine, amphotericin B, aminoglycosides, and cisplatin.

• Other investigational drugs that affect metabolic balance, such as human growth hormone.

• Oral or parenteral magnesium and calcium supplementation.

Patients with the following prior condition are excluded:

History of heart block.